Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | FABP7 | O15540 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 2/20 | 0.34 |
| ▸ | MMP12 | P39900 | 2/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2991857 | 0.98 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL9906294 | 0.98 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL9906293 | 0.94 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL2984452 | 0.94 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL1298015 | 0.84 | EPHX1 (0.47) | EPHX1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2978095 | 0.82 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL9906285 | 0.82 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL28063291 | 0.78 | SLC6A1 (0.41) | EPHX1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL9906287 | 0.78 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL2984602 | 0.78 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139857-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | Targacept Inc. (US) | 2010-01-06 | — | — | EP | claimed |
| WO-2008121686-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | TARGACEPT, INC. (US) | 2008-10-09 | — | — | WO | claimed |
| US-8198296-B2 | Sub-type selective azabicycloalkane derivatives | TARGACEPT, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100173968-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | TARGACEPT, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| EP-2139857-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | Targacept Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008121686-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | TARGACEPT, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173968-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | CHRNB2, CHRNB4, CHRNA4 | CHRNB2 1/4885CHRNA4 3/4885CHRNA7 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.